(19)
(11) EP 2 922 851 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
27.09.2017 Bulletin 2017/39

(45) Mention of the grant of the patent:
26.07.2017 Bulletin 2017/30

(21) Application number: 13798885.3

(22) Date of filing: 19.11.2013
(51) International Patent Classification (IPC): 
C07D 471/04(2006.01)
A61K 31/542(2006.01)
 C07D 519/00(2006.01)
A61P 35/00(2006.01)
(86) International application number:
PCT/US2013/070788
(87) International publication number:
WO 2014/081718 (30.05.2014 Gazette 2014/22)

(54)

AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS

AMINOPYRIMIDINVERBINDUNGEN ALS INHIBITOREN VON T790M-HALTIGEN EGFR-MUTANTEN

COMPOSÉS AMINOPYRIMIDINES EN TANT QU'INHIBITEURS DE MUTANTS D'EGFR CONTENANT T790M

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 20.11.2012 US 201261728487 P
14.03.2013 US 201361784494 P
15.08.2013 US 201361866164 P

(43) Date of publication of application:
30.09.2015 Bulletin 2015/40

(60) Divisional application:
17152475.4 / 3181564

(73) Proprietor: F. Hoffmann-La Roche AG
4070 Basel (CH)

(72) Inventors:
  • BRYAN, Marian C.
    South San Francisco, California 94080 (US)
  • CHAN, Bryan
    South San Francisco, California 94080 (US)
  • HANAN, Emily
    South San Francisco, California 94080 (US)
  • HEFFRON, Timothy
    South San Francisco, California 94080 (US)
  • PURKEY, Hans
    South San Francisco, California 94080 (US)
  • ELLIOTT, Richard Leonard
    Harlow Essex CM19 5TR (GB)
  • HEALD, Robert
    Harlow Essex CM19 5TR (GB)
  • KNIGHT, Jamie
    Harlow Essex CM19 5TR (GB)
  • LAINCHBURY, Michael
    Harlow Essex CM19 5TR (GB)
  • SEWARD, Eileen M.
    Harlow Essex CM19 5TR (GB)

(74) Representative: Kiddle, Simon John et al
Mewburn Ellis LLP
City Tower 40 Basinghall Street London EC2V 5DE
City Tower 40 Basinghall Street London EC2V 5DE (GB)


(56) References cited: : 
WO-A1-2011/079231
   
  • WENJUN ZHOU ET AL: "Novel mutant-selective EGFR kinase inhibitors against EGFR T790M", NATURE, vol. 462, no. 7276, 24 December 2009 (2009-12-24), pages 1070-1074, XP055053374, ISSN: 0028-0836, DOI: 10.1038/nature08622
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).